One Use-Plus SBK Outperforms Femtosecond Laser In Clinical Trials - New Moria Microkeratome Provides All The Benefits Of SBK At A Much More Economical Cost

BUSINESS WIRE

ANTONY, France--(BUSINESS WIRE)--Moria (Paris:MLMOR) has unveiled its new One Use-Plus SBK microkeratome at this year’s meeting of the American Society of Cataract and Refractive Surgery in Chicago. Richard J. Duffey, MD (Mobile, AL, USA) presented the results of his clinical trials. In eyes undergoing SBK (thin-flap LASIK), the flap thickness predictability, speed of visual recovery, higher order aberrations, and smoothness of stromal bed with the Moria One Use-Plus SBK all compared favorably or equally to femtosecond SBK flap technology. The patients treated with the Moria device experienced none of the reported complications unique to Femto-LASIK.

Dr. Duffey also assessed patient comfort with both technologies and found that pain in the first one to five hours after surgery occurred at a much lower frequency and intensity with One Use-Plus SBK than with Femto-SBK (60 kHz). He noted that the One Use-Plus SBK provides all the above advantages at a fraction of the acquisition and operating costs of a femtosecond laser.

Dr. Duffey is not a paid consultant of Moria and has neither a financial relationship with nor a financial interest in the company.

  • <<
  • >>

Comments